Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Neurological, Neuroscience

Getting on Target for Alzheimer’s

In October 2019, Biogen sent shockwaves through the Alzheimer’s community when it reanimated aducanumab, its previously dismissed therapy candidate for Alzheimer’s disease. Upon analysis of additional data supporting aducanumab’s efficacy in patients with longer term, high-dose exposure, Biogen plans to now submit the drug candidate for FDA approval in early 2020. If approved, aducanumab will be the first disease-modifying therapy for Alzheimer’s, which, as a reminder, is currently the only disease on the “top ten” causes of death without treatment. 

Biogen’s surprising, but welcome, reversal not only puts hope on the horizon for a near-term Alzheimer’s treatment, it also – perhaps more importantly – revitalizes work supporting next-generation amyloid beta (Aß)-targeting candidates that can selectively target only its toxic form, beta-amyloid oligomers (AßOs). 

Aducanumab gets us only partially there: 35 percent of patients experienced ARIA-E (brain swelling), revealing the critical need for improved AßO-targeting precision to achieve both greater safety and efficacy. At high doses, aducanumab binds more AßOs, supporting its efficacy, but it also binds amyloid plaque, which is off-target and triggers brain swelling. This unwanted binding of an otherwise benign clump of insoluble protein is what leads to this significant dose-limiting side effect of ARIA-E. Regrettably, definitive data demonstrating the neurotoxic role of AßOs were just becoming available when the clinical development program for aducanumab was devised.  

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!


Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Authors

Neil Cashman

Chief Scientific Officer at ProMIS Neurosciences

James Kupiec

Chief Medical Officer at ProMIS Neurosciences

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts